Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has earned a consensus recommendation of “Hold” from the ten analysts that are presently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $16.71.
Several analysts have recently commented on MNTA shares. Barclays PLC cut shares of Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $20.00 to $17.00 in a research note on Monday, May 22nd. Zacks Investment Research cut shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. BidaskClub raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Maxim Group set a $6.00 price target on shares of Momenta Pharmaceuticals and gave the company a “sell” rating in a research note on Thursday, August 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $26.00 price target on shares of Momenta Pharmaceuticals in a research note on Thursday, August 3rd.
In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 4,116 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $15.07, for a total value of $62,028.12. Following the transaction, the president now directly owns 269,231 shares of the company’s stock, valued at $4,057,311.17. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 43,996 shares of company stock worth $735,755. Insiders own 4.40% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio acquired a new stake in Momenta Pharmaceuticals in the second quarter worth $247,000. Piedmont Investment Advisors LLC acquired a new stake in Momenta Pharmaceuticals in the second quarter worth $244,000. Ameritas Investment Partners Inc. raised its holdings in Momenta Pharmaceuticals by 14.9% in the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 834 shares during the period. California State Teachers Retirement System raised its holdings in Momenta Pharmaceuticals by 1.6% in the second quarter. California State Teachers Retirement System now owns 130,075 shares of the biotechnology company’s stock worth $2,198,000 after purchasing an additional 2,099 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Momenta Pharmaceuticals by 11.0% in the second quarter. The Manufacturers Life Insurance Company now owns 56,563 shares of the biotechnology company’s stock worth $957,000 after purchasing an additional 5,622 shares during the period. Institutional investors own 93.86% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Given Average Rating of “Hold” by Brokerages” was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/09/10/momenta-pharmaceuticals-inc-mnta-given-average-rating-of-hold-by-brokerages.html.
Momenta Pharmaceuticals (NASDAQ MNTA) traded up 2.73% during midday trading on Tuesday, reaching $16.95. The company’s stock had a trading volume of 514,625 shares. The stock’s market capitalization is $1.26 billion. Momenta Pharmaceuticals has a 52-week low of $10.75 and a 52-week high of $19.90. The firm has a 50-day moving average price of $16.30 and a 200 day moving average price of $15.45.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business had revenue of $23.57 million for the quarter, compared to analysts’ expectations of $24.64 million. During the same period in the prior year, the firm earned ($0.31) earnings per share. Momenta Pharmaceuticals’s revenue was down 10.8% compared to the same quarter last year. Equities research analysts predict that Momenta Pharmaceuticals will post ($1.24) EPS for the current fiscal year.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.